From genes and cells to saving lives: NEJM reports positive results for larotrectinib against TRK-fusion cancers

55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent.

Treatment-related mortality of surgery vs. targeted radiation in early lung cancer patients

Among patients older than 80 years, 3.9 percent receiving surgery passed away within the 30-day post-treatment window, compared with 0.9 percent of patients receiving focused radiation.

Lancet Oncology publishes new guidelines on clinical trial designs for patients with brain metastases

New guidelines from an international, multidisciplinary group published in the journal Lancet Oncology describe how to most appropriately address cancer patients with CNS involvement within clinical trials of anti-cancer drugs.

International mentorship is win-win for cancer researchers in U.S. and China

A global problem is now being tackled globally by a unique relationship between Shanghai, China and the University of Colorado Cancer Center.

Latest News from the University of Colorado Cancer Center

@CUCancerCenter on Twitter